Novartis’ Leqvio shows statistically significant LDL-C goal achievement in study

Novartis (NVS) announced “positive” results from V-DIFFERENCE, a Phase IV study evaluating Leqvio compared to placebo, both administered on top of individually optimized lipid-lowering therapy, in patients with high cholesterol who have not achieved guideline-recommended low-density lipoprotein cholesterol goals. These data will be presented in one of the Hot Line sessions of the 2025 European Society of Cardiology Congress, held in Madrid, Spain, from August 29 to September 1. After 90 days of treatment with Leqvio on top of LLT, 85% of patients achieved their guideline-recommended LDL-C target compared to 31% of those receiving placebo on top of LLT. Significant benefits were observed as early as 30 days with 81% of patients achieving LDL-C targets. Results were consistent regardless of age, sex, or cardiovascular risk of trial participants. “The results of the V-DIFFERENCE study add to the growing body of evidence for Leqvio within the VictORION clinical program, which encompasses more than 60,000 patients from 50 countries worldwide,” the company stated.